Related Articles
Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer
Oral low-dose dexamethasone for androgen-independent prostate cancer patients
Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience
A retrospective study of late adverse events in proton beam therapy for prostate cancer
Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?